Dual co-stimulation blockade with dazodalibep and belacept may prevent kidney allograft rejection, according to research presented at the American Transplant Congress.“The purpose of this study was to test dual coast simulation blockade, combining dazodalibep, a non-antibody biologic antagonist of CD40L, with belacept, a CTLA-4-Fc protein, as the sole maintenance anti-rejection therapy for